Por favor, use este identificador para citar o enlazar este ítem:
http://conacyt.repositorioinstitucional.mx/jspui/handle/1000/568| A recommendation for the use of chloroquine, hydroxychloroquine, primaquine, or tafenoquine for prophylaxis against the 2019 novel coronavirus (COVID-19) with note to the ophthalmic considerations | |
| Fouad Alshaban | |
| Acceso Abierto | |
| Atribución-NoComercial-SinDerivadas | |
| With the ongoing pandemic of infectious disease termed coronavirus disease 2019 (COVID-19) caused by the novel coronavirus identified as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), prevention of infection and spread is critical in preventing morbidity and mortality. Prophylaxis, specifically chemoprophylaxis, is particularly critical to breaking the spread and rapid rate of increase of SARS-CoV-2. Pre-exposure and post-exposure prophylaxis are both required components of this public health measure. As the use of anti-malarial agents, specifically the 4-aminoquinolones, chloroquine and hydroxychloroquine, for the treatment of SARS-CoV-2 is now being reported, attention must be turned to their role in the chemoprophylaxis of SARS-CoV-2. In a search of the peer-reviewed medical literature (using MEDLINE and cross-referenced literature), this report is first peer-reviewed publication to present the use of these anti-malarial agents as prophylaxis against SARS-CoV-2. The ophthalmic consideration of the use of these drugs is highlighted in this report. | |
| Eye Reports | |
| 2020 | |
| Preimpreso | |
| https://coronavirus.1science.com/item/9be7bf6e5c747f800e6400c9096841644fa4eb82 | |
| Inglés | |
| VIRUS RESPIRATORIOS | |
| Aparece en las colecciones: | Artículos científicos |
Cargar archivos:
| Fichero | Tamaño | Formato | |
|---|---|---|---|
| 100051.pdf | 1.54 MB | Adobe PDF | Visualizar/Abrir |